Skip to ContentSkip to Navigation
About us Latest news News News articles

Scientists pinpoint genetic risk factors for asthma, hay fever and eczema

31 October 2017

A major international study has pinpointed more than 100 genetic risk factors that explain why some people suffer from asthma, hay fever and eczema. In this worldwide study UMCG-researchers Judith Vonk and Gerard Koppelman were collaborating with scienstist from Australia, USA and Europe. It has been published in the prestigious journal Nature Genetics.

This was the first study designed specifically to find genetic risk factors that are shared among the three most common allergic conditions. Asthma, hay fever and eczema are allergic diseases that affect different parts of the body: the lung, the nose and the skin. From earlier research was already known that they were similar at many levels. For example, known was that the three diseases shared many genetic risk factors. But absolutely not known was exactly where in the genome those shared genetic risk factors were located. “This is important to know because it tells us which specific genes, when not working properly, cause allergic conditions. This knowledge helps us understand why allergies develop in the first place and, potentially, gives us new clues on how they could be prevented or treated”, dr Gerard Koppelman said.

In this study the researchers analysed the genomes of 360,838 people and pinpointed 136 separate positions in the genome that are risk factors for developing these conditions. This means that if someone inherits these genetic risk factors from his or her parents, it will predispose him or her to all three allergic conditions.

Dr Koppelman said those 136 genetic risk factors influenced whether 132 nearby genes were switched on or off. “We think that these genes influence the risk of asthma, hay fever and eczema by affecting how the cells of the immune system work,” he said. “Importantly, we have identified several drugs that we believe could be targeted at some of these genes to treat allergies. The first step would be to test those drugs in the laboratory.”

The study involved collaborators from Australia, Germany, the Netherlands, Norway, Sweden, the UK and the US. Vonk and Koppelman used data from the biobank Lifelines.

Last modified:12 March 2020 9.33 p.m.
View this page in: Nederlands

More news

  • 29 February 2024

    Vici grants for four UG/UMCG scientists

    The Dutch Research Council (NWO) has awarded Vici grants, worth up to €1.5 million each, to Nathalie Katsonis, Edwin Otten and Alexandra Zhernakova. Professor of Coastal Ecology Tjisse van der Heide has also received a Vici grant for research he...

  • 27 February 2024

    New study finds early life economic conditions impact risk of type-2 diabetes in adulthood

    A new study by current and former FEB researchers Rob Alessie, Viola Angelini, Gerard van den Berg, Jochen Mierau and Gianmaria Niccodemi sheds light on the long-term health implications of economic conditions in early life. The study, titled...

  • 05 February 2024

    Three UG researchers nominated for Woman in the Media Award 2023

    Three women affiliated with the RUG/UMCG have been nominated for the Woman in the Media Award 2023: Léonie de Jonge, Myrthe Hol and Iris Sommer. This election aims to encourage female experts and public figures to appear more in the media and to...